New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 15, 2013
08:08 EDTMNTAMomenta Pharma stills sees 2013 operating cash use about $90M
Momenta confirmed its guidance, previously provided in November, for total operating expenses, excluding stock-based compensation and net of collaborative revenues, of approximately $30M per quarter in 2013. For 2013, Momenta is projecting that its net cash usage will average approximately $20M-$24M per quarter for a total operating cash usage of approximately $90M.
News For MNTA From The Last 14 Days
Check below for free stories on MNTA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
10:36 EDTMNTAHigh option volume stocks
Subscribe for More Information
September 8, 2014
09:27 EDTMNTALeerink biotech analyst holds a luncheon meeting with a conference call
Biotech Analyst Schwartz provides an update on key trends and controversies for marketed MS therapies and discusses new data presented at ACTRIMS-ECTRIMS at a Luncheon Meeting with an Analyst/Industry conference call to be held in Boston on September 11 at 12:15 pm.
08:32 EDTMNTAMomenta Pharma exercises option to acquire antibody program from AnaptysBio
AnaptysBio announced that Momenta Pharma has exercised its option to acquire a novel antibody program from AnaptysBio. Upon payment of an option exercise fee to AnaptysBio, Momenta has received worldwide rights to therapeutic antibodies against a target selected based upon the anti-inflammatory effects of IVIg. The aforementioned option right was granted by AnaptysBio to Momenta under an agreement signed between the companies in December 2013.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use